drugset / Trial / NCT06314880
Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The research objective is to evaluate the safety and tolerability of the recombinant Group B meningococcal vaccine (E. coli) and explore its preliminary immunogenicity.
Timeline
- Start
- 2023-07-22
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Meningococcal Group B Vaccine (E. Coli) | Vaccine | 60 ug | — |
| Subject | Recombinant Meningococcal Group B Vaccine (E. Coli) | Vaccine | 100 ug | — |
Indications
No indication recorded.